ArticleBioorganic & medicinal chemistry2011
Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors.
Article in Bioorganic & medicinal chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer.Investigational new drugs · 2023Trial
- Synthesis, characterization, and DFT study of a novel pyrido[2',3':4,5]pyrimido[2,1-b][1,3]thiazines via Michael addition and intramolecular cyclization.BMC chemistry · 2026Article
- FtsZ as a novel target for antibiotics development: Promises and challenges.Acta pharmaceutica Sinica. B · 2025Review
- Multicomponent synthesis of pyrido[2,3-RSC advances · 2023Article
- Filamentous temperature sensitive mutant Z: a putative target to combat antibacterial resistance.RSC advances · 2023Review
- Strategic incorporation of fluorine in the drug discovery of new-generation antitubercular agents targeting bacterial cell division protein FtsZ.Journal of fluorine chemistry · 2017Article
- Mutation at G103 of MtbFtsZ Altered their Sensitivity to Coumarins.Frontiers in microbiology · 2017Article
- Article
- Recent advances in the discovery and development of antibacterial agents targeting the cell-division protein FtsZ.Bioorganic & medicinal chemistry · 2016Review
- Targeting the Bacterial Division Protein FtsZ.Journal of medicinal chemistry · 2016Review
- One-Pot Synthesis of Benzo[4,5]imidazo[2,1-a]isoquinolines and Isoquinolino[3,4-b]quinoxalines via Tandem Cyclization Strategies.The Journal of organic chemistry · 2016Article
- Article
- Cell division inhibitors with efficacy equivalent to isoniazid in the acute murine Mycobacterium tuberculosis infection model.The Journal of antimicrobial chemotherapy · 2015Article
- Drug discovery targeting cell division proteins, microtubules and FtsZ.Bioorganic & medicinal chemistry · 2014Review
- A trisubstituted benzimidazole cell division inhibitor with efficacy against Mycobacterium tuberculosis.PloS one · 2014Article
- SAR studies on trisubstituted benzimidazoles as inhibitors of Mtb FtsZ for the development of novel antitubercular agents.Journal of medicinal chemistry · 2013Article
- A novel quinoline derivative that inhibits mycobacterial FtsZ.Tuberculosis (Edinburgh, Scotland) · 2013Article
- Comparison of small molecule inhibitors of the bacterial cell division protein FtsZ and identification of a reliable cross-species inhibitor.ACS chemical biology · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
A series of pyridopyrazine and pyrimidothiazine derivatives have been synthesized and their activity against FtsZ from Mycobacterium tuberculosis (Mtb) and in vitro antibacterial activity against Mtb H(37)Ra and Mtb H(37)Rv are reported. Certain analogs described herein showed moderate to good inhibitory activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.